ストックスクリーナーアプリを入手
100.07
1.00%
-1.01
プレマーケット:
99.39
-0.68
-0.68%
前日終値:
$101.08
開ける：
$100.77
24時間の取引高:
1.99M
Relative Volume:
0.89
時価総額：
$19.65B
収益：
$4.58B
当期純損益:
$870.87M
株価収益率:
22.75
EPS:
4.3988
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
-1.88%
1か月 パフォーマンス:
+1.17%
6か月 パフォーマンス:
+29.04%
1年 パフォーマンス:
+35.65%
1日の値動き範囲:
$99.28
$101.25
1週間の範囲:
$98.85
$105.06
52週間の値動き範囲:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
100.07 | 19.84B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Value Investing Opportunity: Incyte Corp. (NASDAQ:INCY) Presents a Compelling Case - Chartmill
Incyte (INCY) Gains European Recommendation for Zynyz Therapy - GuruFocus
Incyte (INCY) Gains EMA Panel Support for Expanded Use of Zynyz - GuruFocus
Incyte gets positive CHMP opinion for anal cancer drug Zynyz - StreetInsider
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Yahoo Finance
Ruffer LLP Has $3.74 Million Holdings in Incyte Corporation $INCY - MarketBeat
Undercovered Dozen: Incyte, Annaly Capital, ImmunityBio And More - Seeking Alpha
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results - Business Wire
INCY Stock Price and Chart — NASDAQ:INCY - TradingView
Here's Why Incyte (INCY) is a Strong Momentum Stock - Yahoo Finance
Incyte Corporation $INCY Stock Position Lowered by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Why Incyte (INCY) is a Top Value Stock for the Long-Term - Yahoo Finance
Incyte Corporation $INCY Stock Position Raised by Massachusetts Financial Services Co. MA - MarketBeat
Engaging In Insider Activity, Patrick Mayes At Incyte Exercises Options Worth $0 - Benzinga
Thomas Tray Decides To Exercise Options At Incyte Worth $0 - Benzinga
Engaging In Insider Activity, Matteo Trotta At Incyte Exercises Options Worth $0 - Benzinga
Breaking Update: PABLO CAGNONI Engages In Options Exercise At Incyte Realizing $0 - Benzinga
What Investors Should Know Before Buying Incyte Stock (NASDAQ:INCY) - Seeking Alpha
Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains - 富途牛牛
Reassessing Incyte (INCY) Valuation After Wells Fargo’s Neutral Downgrade - Yahoo Finance
Wells Fargo & Company Downgrades Incyte (NASDAQ:INCY) to Hold - MarketBeat
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte (INCY) Faces Downgrade and Adjusted Price Target by Wells Fargo - GuruFocus
Incyte (INCY) Faces Downgrade with Revised Price Target by Wells Fargo | INCY Stock News - GuruFocus
IBM To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Wells Fargo downgrades Incyte stock to Equal Weight as upgrade thesis plays out - Investing.com
New Incyte Drug Combo Shows Power Against Deadly Lymphoma - mychesco.com
EC approves label expansion of INCY's lymphoma drug Minjuvi - MSN
Why Incyte (INCY) Stock Is Trading Up Today - Finviz
Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain? - Yahoo Finance
Incyte (INCY) Receives Updated Buy Rating from TD Cowen | INCY S - GuruFocus
Incyte (NASDAQ:INCY) Given New $128.00 Price Target at TD Cowen - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Earnings Preview: What To Expect From Incyte's Report - Barchart.com
GRIMES & Co WEALTH MANAGEMENT LLC Sells 16,883 Shares of Incyte Corporation $INCY - MarketBeat
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH) - The Globe and Mail
Lobbying Update: $70,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Finviz
Incyte Corporation (INCY) Stock Analysis: Strong Revenue Growth and Strategic Developments in the Biotech Sector - DirectorsTalk Interviews
Incyte Corp. stock underperforms Monday when compared to competitors - MSN
ImmunityBio, Xencor Drugs Win E.U. Nods - Los Angeles Business Journal
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
What margin trends mean for Incyte Corporation stockOil Prices & High Return Trade Guides - Улправда
Incyte Corporation $INCY Stock Holdings Increased by Cerity Partners LLC - MarketBeat
Will Incyte Corporation (ICY) stock beat value stocks2025 Analyst Calls & Smart Investment Allocation Tips - ulpravda.ru
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Incyte jumps amid takeover speculation - MSN
Bull of the Day: Eli Lilly (LLY) - Finviz
This Biotech Stock Eyes Fresh Entry With 522% Earnings Growth Seen - Investor's Business Daily
Can Incyte Corporation stock reach $100 price targetExit Point & Scalable Portfolio Growth Methods - ulpravda.ru
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
2.16%
大文字化:
|
ボリューム (24 時間):